ストックスクリーナーアプリを入手
5.61
2.26%
-0.13
プレマーケット:
5.48
-0.13
-2.32%
前日終値:
$5.74
開ける：
$5.83
24時間の取引高:
229.92K
Relative Volume:
1.01
時価総額：
$33.04M
収益：
$14.50M
当期純損益:
$-15.41M
株価収益率:
-0.4282
EPS:
-13.1
ネットキャッシュフロー:
$-13.04M
1週間 パフォーマンス:
+10.87%
1か月 パフォーマンス:
+12.65%
6か月 パフォーマンス:
+128.98%
1年 パフォーマンス:
-13.69%
1日の値動き範囲:
$5.311
$5.83
1週間の範囲:
$4.94
$6.28
52週間の値動き範囲:
$1.91
$9.1391
Vivos Therapeutics Inc Stock (VVOS) Company Profile
名前
Vivos Therapeutics Inc
セクター
電話
(866)908-4867
住所
7921 SOUTHPARK PLAZA,, LITTLETON
VVOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
5.61 | 33.04M | 14.50M | -15.41M | -13.04M | -13.10 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Vivos Therapeutics Inc (VVOS) 最新ニュース
VVOS Stock Price and Chart — NASDAQ:VVOS — TradingView«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Best Momentum Stocks to Buy for January 8th - MSN
Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health Care - PR Web
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December - Defense World
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar - Simply Wall St
Vivos Therapeutics announces $3.5 million stock offering - Investing.com
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - StockTitan
Vivos Therapeutics announces funding boost - Proactive Investors USA
Vivos Therapeutics (NASDAQ:VVOS) Stock Price Up 6.9% – What’s Next? - Defense World
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy - Yahoo Finance
FDA-Cleared Therapy for Pediatric Sleep Apnea From Vivos Offers Parents and Providers New Hope - PR Web
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., "New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind" - Big News Network
Vivos, Cellev8 Launch Strategic Sleep Apnea Venture: FDA-Cleared Devices Meet Breakthrough Nutraceuticals - StockTitan
Water Tower Research Publishes Initiation of Coverage Report on - News Channel Nebraska
Vivos and SleepImage © Revolutionize Sleep Apnea Diagnostics with Affordable Home Sleep Testing Solutions - PR Web
Vivos Therapeutics shareholders elect directors, approve equity plan By Investing.com - Investing.com South Africa
Vivos Therapeutics shareholders elect directors, approve equity plan - Investing.com India
Sleep Apnea: Vivos' FDA-Cleared Technology Offers Revolutionary, Non-Invasive Hope for America's Stealth Epidemic - PR Web
Medicare to reimburse for Vivos CARE sleep apnea devices - MSN
Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS) - Defense World
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings call: Vivos Therapeutics sees revenue growth in Q3 2024 - Investing.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call Transcript - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Vivos Therapeutics Inc - GuruFocus.com
Vivos Therapeutics Inc (VVOS) Quarterly 10-Q Report - Quartzy
Earnings call: Vivos Therapeutics sees revenue growth in Q3 2024 By Investing.com - Investing.com Nigeria
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones - TipRanks
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 - Proactive Investors USA
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Q3 Revenue Jumps 17% as FDA Approves Pediatric OSA Treatment | VVOS Stock News - StockTitan
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - The Manila Times
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely - Simply Wall St
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance - MSN
Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes - Proactive Investors Australia
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - Yahoo Finance
Vivos Granted Reimbursement Codes for Oral Appliances for OSA - Sleep Review
Vivos secures new AMA medical codes for OSA devices - Investing.com
Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments - Stocks Telegraph
Vivos secures new AMA medical codes for OSA devices By Investing.com - Investing.com South Africa
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - The Manila Times
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment - Proactive Investors UK
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
Vivos Therapeutics Inc (VVOS) 財務データ
収益
当期純利益
現金流量
EPS
3.55%
大文字化:
|
ボリューム (24 時間):